The National Institutes of Health’s Post

This breakthrough could significantly improve early detection and timely intervention, allowing more patients to benefit from targeted treatments sooner. It’s exciting to see how research like this is transforming the landscape of neurological care and enhancing patient outcomes. #AlzheimersResearch #BloodTest #Neurology #HealthcareInnovation #Research

Better disease diagnosis and monitoring tools are key to the development of better therapies.

Accurate blood test for Alzheimer’s disease ✔ A blood test identified Alzheimer’s disease correctly in older adults with about 90% accuracy ✔ Such tests could help speed the diagnosis of Alzheimer’s disease in primary care clinics and help more people access treatments Read the full National Institutes of Health article 👇 https://lnkd.in/eXeGTm-g #alzheimers #bloodtest #biomarkers #diagnostics

For those who have asked me about the policy work I have been doing in the Alzheimer’s disease space, here is the PubMed link to my first, first-author paper, titled “Diagnostic Hesitancy of Primary Care Physicians in Puerto Rico Towards Alzheimer’s Disease: Opportunities for Transformation”, published in September. The findings of this study, with 100+ Puerto Rican PCPs, highlights the need to better prepare for the challenges of diagnosis and management of ADRD, when the “brain drain” of specialists is putting Puerto Rican PCPs at the helm of dealing with a growing ADRD epidemic. Addressing challenges faced by PCPs in diagnosing and managing ADRD is essential to ensure timely and accurate diagnosis –and appropriate care–for people living with the disease. National Institute on Aging (NIA) https://lnkd.in/g6KkAx-2

#AAIC24 News: APS2 and p-tau217 ratio detect Alzheimer's disease in primary and secondary care. Click to read the full story: https://bit.ly/4djzIlp --- This activity is supported by an educational grant from Lilly. #Alzheimers #AlzheimersAwareness #AAIC #AD #medicaleducation #continuingmedicaleducation #cme #independentmedicaleducation #ime #SpringerIME

Principal component-based clinical aging clocks identify signatures of healthy aging and targets for clinical intervention https://lnkd.in/eQ7W9UZ8

𝐍𝐞𝐰𝐞𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐚 𝐠𝐫𝐨𝐮𝐧𝐝𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐏𝐚𝐫𝐤𝐢𝐧𝐬𝐨𝐧’𝐬 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐬𝐭𝐮𝐝𝐲 🚀 Partnering with three distinguished centers, this study is set to redefine the approach to treating Parkinson’s disease using 𝐑𝐞𝐚𝐥-𝐖𝐨𝐫𝐥𝐝 𝐃𝐚𝐭𝐚 (#RWD). 🔎 Funded by The Michael J. Fox Foundation for Parkinson's Research and led by Prof. Maria Teresa Pellecchia at University Hospital San Giovanni di Dio e Ruggi d'Aragona, the study seeks to validate algorithms for treatment optimization by analyzing patient symptoms and responses to medication. It leverages the innovative 𝐒𝐨𝐭𝐮𝐫𝐢 mobile app and smart device over a 6-month period and prioritizes the collection of free-living data to better understand the daily challenges faced by #Parkinson's patients. 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗺𝗼𝗿𝗲: https://lnkd.in/daNECx7Q Newel Health #Parkinsons #ParkinsonsStudy #DigitalHealth #Innovation

💫 Our most recent peer-reviewed publication is out! 💫 With funding from a $1.9 million grant from The National Institutes of Health's National Heart, Lung, and Blood Institute, researchers from Nationwide Children's Hospital and two other children’s hospitals in the U.S. will study the effectiveness of video DOT and health coaching to improve adherence to hydroxyurea in kids and teens with sickle cell disease. Building upon a 2014 pilot study by Dr. Susan Creary, a pediatric hematologic oncologist with Nationwide Children's Hospital, the ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness) study aims to boost adherence and improve care and outcomes for children and adolescents with sickle cell disease using Scene’s medication engagement program. Sickle cell disease disproportionately affects Black communities and exacerbates health equity disparities in populations with limited access to healthcare resources. With an emphasis on equity, the study allows for a more heterogeneous population to be recruited because gaps in access to technology and high-speed internet will be addressed. For kids and teens living with sickle cell disease, better adherence to hydroxyurea can improve their quality of life and allow them to do more of the things they enjoy. Read the study: https://lnkd.in/eYGFXBMz #SickleCellDisease #SCD

Unveiling Patient Patterns to Transform ALS Care Understanding how diseases progress in different patients is crucial for better treatment and care. Imagine if we could sort patients into groups based on their unique disease journeys. That's exactly what the new approach, ClusTric, aims to do! ClusTric uses advanced data techniques, combining triclustering and hierarchical clustering, to uncover complex patterns in disease progression that simpler methods miss. This approach is especially valuable for conditions like Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease with unpredictable and varied progression. In a fascinating case study, researchers applied ClusTric to patient data from the Lisbon ALS Clinic and validated it with clinical trial data. They discovered four distinct ALS progression groups: slow progressors, moderate bulbar and spinal progressors, and fast progressors. This stratification can guide personalized clinical decisions and improve patient care. Compared to other top methods, ClusTric proved more effective in capturing the diverse progression of ALS with fewer, but more clinically relevant, patient groups. This breakthrough in understanding ALS progression patterns is a game-changer, paving the way for tailored treatments and better outcomes for patients. #ALSResearch #PatientCare #DataScience #MedicalInnovation #PersonalizedMedicine #DiseaseProgression #ClusTric #HealthcareTransformation https://lnkd.in/dFQRahRD

Excited to share our latest research, led by Berenice Silva MD PhD MSc Safety of High Efficacy Therapies in Older Adults with Multiple Sclerosis: A Real-World Evidence Study 📊 🔹 As the number of older adults living with Multiple Sclerosis (MS) continues to rise, so does the use of high efficacy therapies (HETs) in this population. 🔹 However, until now, there has been a lack of data on the safety of HETs in people with MS aged 50 and over. 🔹 Our study provides new insights, showing that the short-term use of HETs in people with MS over 50 years old appears to be safe. This is a crucial step forward in optimizing treatment strategies for this growing patient population. Link https://lnkd.in/g8FpQgFS